Last reviewed · How we verify
NCT04440371: NBUVB
Phototherapy Combination With Topicals in Vitiligo
NA trial testing Tacrolimus 0.1% ointment twice daily plus NBUVB 3 times weekly in Vitiligo, Generalized in 40 participants. Status unknown.
30 July 2023
Quick facts
| Lead sponsor | Jordan University of Science and Technology |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 40 |
| Start date | 21 June 2020 |
| Primary completion | 30 July 2023 |
| Estimated completion | 30 December 2023 |
| Sites | 1 location across Jordan |
Drugs / interventions tested
- Tacrolimus 0.1% ointment twice daily plus NBUVB 3 times weekly
- Calcipotriol/Betamethasone ointment plus NBUVB
Conditions studied
- Vitiligo, Generalized — all drugs for Vitiligo, Generalized →
Sponsor
Jordan University of Science and Technology
Who can join
18 and older, any sex, with Vitiligo, Generalized. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Patients will be included in a randomized controlled clinical trial, will enroll only adult vitiligo patients with surface area of at least 10% who are being followed in the outpatient dermatology clinics of King Abdullah University Hospital (KAUH) and are planned to start on phototherapy Narrow Band Ultraviolet light B (NBUVB), regardless if they have previous treatment for their disease, one month wash off period will be given for patients who are already on phototherapy or other treatments for vitiligo.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Comparison of the efficacy of tacrolimus 0.1% ointment vs calcipotriol/betamethasone in combination with NBUVB in treatment of vitiligo.
Alshiyab D, Al-Qarqaz F, Ba-Shammakh S, Al-Fakih A, et al · · 2023 · cited 2× · PMID 37644869 · DOI 10.1080/09546634.2023.2252119
Verify or expand the search:
- PubMed search for NCT04440371
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Vitiligo, Generalized
Currently open trials in the same condition.
- NCT06327321 — Vitiligo Treatment by Targeting TYK2 Mediated Responses · Phase 2 · recruiting
Other Jordan University of Science and Technology trials
Trials by the same sponsor.
- NCT07504614 — Pre-etched Bioactive Versus Resin- Based Fissure Sealant for Permanent Molars Affected With Molar Incisor Hypomineraliza · NA · enrolling by invitation
- NCT07522216 — Effect of Clear Aligner Wear Protocol on External Root Resorption · NA · active not recruiting
- NCT07167654 — Smartphone Application to Support Mothers at Risk of Postpartum Depression · NA · active not recruiting
- NCT07318298 — Effect of Injectable Hyaluronic Acid (HYADENT BG (HA)) on Bone Healing in Extraction Sockets · NA · recruiting
- NCT06635278 — Mindfulness Meditation: Alleviating Symptoms and Inflammation in Nurses · NA · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04440371 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Jordan University of Science and Technology
- Last refreshed: 13 September 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04440371.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing